2 completed. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow Robert Redner, MD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy mitoxantrone + etoposide + gemtuzumab ozogamicin - Acute Myeloid Leukemia | Phase 2 | Completed | Robert Redner, MD | 16 | 2019-02-28 | 2025-02-20 |
| Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma Bendamustine, Lenalidomide, Dexamethasone - Myeloma | Phase 1 | Completed | Robert Redner, MD | 29 | 2008-02-01 | 2017-07-31 |
Leukemia, Myeloid, Acute (1) · Neoplasms, Plasma Cell (1)
Anti-Bacterial Agents (1) · Aspirin (1) · Bendamustine Hydrochloride (1) · Dexamethasone (1) · Etoposide (1) · Gemtuzumab (1) · Lenalidomide (1) · Mitoxantrone (1)
United States (2)
Redner Robert, MD (1) · Robert L Redner, M.D. (1)